Which Is Worse: Parkinson’s or Multiple Sclerosis?

Neither Parkinson’s disease nor multiple sclerosis is categorically “worse” than the other. Research directly comparing the two conditions finds that both reduce quality of life to a similar degree, with roughly equal proportions of patients reporting diminished well-being regardless of which diagnosis they carry. What makes them feel so different to the people living with them is the timing, trajectory, and specific functions each disease attacks first. Parkinson’s typically arrives later in life and progresses steadily, while MS often strikes decades earlier and follows a less predictable path.

Two Diseases on Very Different Timelines

Parkinson’s disease is primarily a condition of older adults. It usually appears after age 60, though earlier-onset cases exist, and it progresses gradually over years to decades. The hallmark is a slow loss of dopamine-producing neurons in the brain, leading to tremor, stiffness, and eventually difficulties with walking, swallowing, and cognition. The course is relatively predictable in broad strokes: symptoms worsen over time, with the rate varying from person to person but the general direction always the same.

Multiple sclerosis works differently. It most often shows up between the ages of 20 and 40, which means it can disrupt careers, young families, and long-term financial plans in ways that Parkinson’s typically does not. The immune system attacks the protective coating around nerve fibers, and the damage can appear almost anywhere in the central nervous system. About 85 percent of people with MS start with a relapsing-remitting course, in which symptoms flare up and then partially or fully resolve, sometimes for months or years at a stretch. Many of those cases eventually transition to a progressive phase, and a smaller percentage are progressive from the start. That unpredictability is itself a source of distress: each relapse is a reminder that the disease is chronic and that recovery from the next flare is not guaranteed.¹

Globally, Parkinson’s is far more common among older adults. In 2021, the worldwide prevalence of PD in people aged 55 and older was estimated at roughly 10.8 million cases, compared with about 761,000 cases of late-onset MS in the same age bracket.² That gap partly reflects the age of onset: younger people with MS are not captured in those late-onset figures. But it means PD accounts for a much larger share of the global disability burden among seniors.

Quality of Life Drops Comparably

When researchers have put the two diseases side by side using the same quality-of-life instruments, the results are strikingly similar. A study that controlled for disease duration found that 88 percent of Parkinson’s patients and 84 percent of MS patients showed reduced quality of life, and the overall impact was comparable once clinical disability level was accounted for.³ The specific domains that suffer most do differ. Parkinson’s tends to erode motor control and independence at a steady pace, while MS can leave someone feeling nearly normal for long stretches before a relapse knocks them back. But the bottom line for day-to-day well-being is similar.

The same pattern appears in palliative care research. A secondary analysis of trial data examining the symptom burden in patients with advanced neurological conditions found that mean palliative care need scores did not differ significantly between MS, Parkinson’s-related diseases, and motor neuron disease groups.⁴ In advanced stages, both diseases converge toward a common cluster of difficulties: immobility, communication problems, fatigue, and psychological distress.

Mobility Breaks Down in Different Ways

Both diseases eventually compromise movement, but they attack different aspects of it. A multicenter study comparing mobility across stroke, Parkinson’s, and MS found that people with MS performed worse on tests of dynamic balance: they took longer on the Timed Up and Go Test (about 16.7 seconds versus 11.4 seconds for PD) and scored lower on the Dynamic Gait Index. Parkinson’s patients, on the other hand, had worse static balance and body-position control, scoring lower on the Berg Balance Scale alongside stroke patients.⁵

In practical terms, this means MS tends to make walking on uneven surfaces, turning quickly, and moving through crowded environments especially hazardous. Parkinson’s makes standing still, getting up from a chair, and maintaining posture more difficult. Both increase fall risk, but for different reasons. A physical therapist designing an exercise program for each condition would focus on almost opposite priorities, which is one reason the two diseases feel so different from the inside even though they both end up limiting independence.

Fatigue and Pain

Fatigue is one of the most disabling symptoms in both diseases, and it is often the symptom patients rank as most bothersome, ahead of the motor problems that outsiders notice. Using the Fatigue Severity Scale, researchers found that about 64 percent of people with Parkinson’s and 74 percent of people with MS experienced severe fatigue. Average fatigue scores were slightly higher in the MS group, though the difference was modest.⁶ Apathy scores, meanwhile, were virtually identical between the two groups, suggesting that the overlap in non-motor symptoms goes deeper than fatigue alone.

Pain is another shared burden that gets underappreciated. A review of the pain literature found that both PD and MS patients without cognitive impairment tend to experience heightened pain overall, particularly in its emotional and motivational dimensions. People with either condition often report that pain feels more distressing and harder to tolerate than it would for someone without a neurological disease, even when the raw sensation is not more intense. One exception is that Parkinson’s patients specifically showed a lower threshold for heat pain, a finding not replicated in MS.⁷

Depression Hits Both Groups Hard

Depression is common in both conditions, though estimating its prevalence depends heavily on which screening tool is used. An Iranian study measuring depression across several neurological diseases found that on one widely used scale, about 44 percent of Parkinson’s patients and 45 percent of MS patients met criteria for depression. On a clinician-rated scale, the numbers diverged more: roughly 56 percent for PD versus 39 percent for MS. And on a third diagnostic checklist, about 65 percent of PD patients and 36 percent of MS patients qualified.⁸

The inconsistency across instruments is not a flaw in the research so much as a reflection of how differently depression presents in these two diseases. Parkinson’s-related depression often looks like flat affect, social withdrawal, and loss of initiative, which can be hard to distinguish from the motor slowness and facial masking the disease itself causes. MS-related depression may be more obviously linked to mood swings, grief over lost abilities, and the psychological weight of uncertainty. Both are undertreated, partly because patients and doctors alike may attribute the symptoms to “just part of the disease” rather than a treatable condition layered on top of it.

The Treatment Gap

This is the area where the two diseases differ most dramatically, and not in the direction many people expect. Multiple sclerosis has seen a revolution in disease-modifying therapies over the past two decades, with a range of drugs now approved for relapsing MS and the first therapies reaching progressive MS. These treatments do not cure the disease, but they can substantially reduce the frequency and severity of relapses and slow the accumulation of disability.⁹

Parkinson’s disease has no equivalent. Every approved PD treatment is symptomatic: it manages tremor, stiffness, or slowness without slowing the underlying loss of brain cells. The mainstay medication, levodopa, remains the most effective option more than 50 years after its introduction, but it comes with its own problems. Over time, many patients develop the “on-off phenomenon,” in which the drug’s effectiveness fluctuates unpredictably, sometimes working well and sometimes leaving the person essentially unmedicated despite taking the pill on schedule. Adjunct therapies such as safinamide have shown some benefit in smoothing out these fluctuations, but they do not change the disease’s trajectory.¹⁰

For someone weighing which disease is “worse,” this matters enormously. A 30-year-old diagnosed with relapsing MS today has access to therapies that could keep them relatively stable for years or decades. A 65-year-old diagnosed with Parkinson’s faces a progressive condition with no approved treatment to slow its advance. The MS field’s success with disease-modifying therapies is now being studied as a model for developing similar approaches in PD, but that pipeline has not yet delivered results to patients.

What Caregivers Go Through

The burden on family members and caregivers is substantial for both conditions and, like quality of life, roughly comparable. A study of MS caregivers found that their levels of distress and reduced quality of life were similar to those reported by elderly spouses caring for someone with long-standing Parkinson’s disease.¹¹ In both cases, the neuropsychiatric symptoms, including mood changes, apathy, and cognitive difficulties, were a bigger driver of caregiver distress than the physical symptoms. A patient who cannot walk but is emotionally engaged is often easier to care for than a patient who can still walk but has become withdrawn or irritable.

The financial picture is complicated and shifts as each disease progresses. An analysis of service costs found that MS and Parkinson’s follow different spending trajectories. In MS, formal care costs from professionals, hospital stays, and medications stay relatively stable as the disease worsens, but informal care costs from family and friends climb steeply. For people with progressive MS, unpaid caregivers accounted for roughly three-quarters of total costs. In Parkinson’s, formal care costs rise more sharply as the disease advances, while informal care costs grow at a slower rate.¹² The practical takeaway is that MS families absorb more of the caregiving burden themselves, while Parkinson’s families may face higher out-of-pocket costs for professional care as the condition advances.

Living with Uncertainty Versus Living with Certainty

One of the most underappreciated differences between the two diseases is psychological rather than physical. Parkinson’s progression is largely predictable. You know, roughly, what is coming. The news is bad, but the road is mapped. MS offers no such clarity. A person with relapsing-remitting MS might go years without a major flare, then wake up one morning unable to see out of one eye or unable to feel one leg. Each relapse strains coping mechanisms and forces the person to re-evaluate plans they had assumed were settled.¹

That uncertainty ripples outward. Research on the long-term social effects of MS found that men with the disease had a 21 percent higher risk of divorce compared with matched controls, even after accounting for age and geographic factors. The increased risk was not found in women with MS, which may reflect gendered expectations around caregiving or other social dynamics the study did not fully unpack.¹³ Parkinson’s takes its toll on relationships too, especially as cognitive changes emerge and caregiving demands increase, but the MS data highlight how the disease’s unpredictability can uniquely fracture the social support systems people depend on.

Age of Onset Changes Everything

Many of the differences between PD and MS become clearer once you consider when each disease typically appears. A Parkinson’s diagnosis at 68 may mean a decade or more of gradual decline, but it arrives after the person has already built a career, raised children, and established financial security. An MS diagnosis at 28 may carry a better long-term survival rate and access to disease-modifying drugs, but it lands in the middle of the years when people are finishing education, establishing careers, having children, and saving for retirement.

Lost employment costs illustrate the difference concretely. Even in the MS population alone, people with progressive forms of the disease lost more in employment income than those with relapsing-remitting MS.¹² Extrapolated over the longer working-life window that a young MS patient faces, the cumulative economic damage can be severe, not just in lost wages but in reduced retirement savings, limited career advancement, and higher lifetime insurance costs. Parkinson’s patients may face a shorter period of employment disruption before retirement age, though the disease still causes financial strain through medication costs and caregiving needs.

When “Worse” Depends on What You Fear Most

People asking which disease is worse usually have a specific fear in mind, and the answer shifts depending on what that fear is. If your greatest concern is physical disability progressing without any way to slow it down, Parkinson’s is arguably harder to face right now because no disease-modifying therapy exists.⁹ If your greatest fear is being diagnosed young and watching your career, relationships, and identity get reshaped by a disease that could flare unpredictably for decades, MS carries a particular kind of weight that Parkinson’s does not.

If you are worried about day-to-day quality of life, the evidence suggests neither disease lets you off easy. Both cause severe fatigue in the majority of patients.⁶ Both carry high rates of depression. Both alter the experience of pain. And both place enormous demands on families, with caregiver distress levels that are comparable across the two conditions.¹¹

How the Two Diseases Look in Late Stages

In their advanced phases, Parkinson’s and MS converge more than they diverge. Swallowing difficulties, communication problems, and immobility become prominent in both, and palliative care needs are similar in type and severity.⁴ Advanced Parkinson’s often brings cognitive decline, hallucinations, and severe postural instability that confines people to a wheelchair or bed. Advanced MS may involve near-total loss of limb function, bladder and bowel dysfunction, and cognitive impairment, though the specific constellation depends on where in the nervous system the damage has accumulated over the years.

One practical difference is that Parkinson’s patients in late stages may still respond to levodopa for certain motor symptoms, even if the response is unpredictable. MS patients in a secondary progressive phase have fewer pharmacological options for symptom management, and the available drugs tend to be more effective earlier in the disease. Both groups are widely acknowledged to be underserved by palliative care systems, which have historically focused on cancer and are only recently expanding to cover long-term neurological conditions systematically.

The global disability burden associated with Parkinson’s has been growing rapidly, with disability-adjusted life years increasing by roughly 165 percent between 1990 and 2021, compared with a 117 percent increase for late-onset MS over the same period.² Part of that gap reflects the aging of global populations, which disproportionately increases Parkinson’s prevalence. But it also means that in terms of sheer public health impact, PD is the larger problem and likely to become more so as populations continue to age through 2050.